Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. | UCSF Helen Diller Family Comprehensive Cancer Center

Author List

Robert C, Ribas A, Hamid O, Daud A, Wolchok JD, Joshua AM, Hwu WJ, Weber JS, Gangadhar TC, Joseph RW, Dronca R, Patnaik A, Zarour H, Kefford R, Hersey P, Zhang J, Anderson J, Diede SJ, Ebbinghaus S, Hodi FS

Publication

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Publication ID (Profile URL)

https://researcherprofiles.org/profile/1411044

Publication Year

2017

PubMed ID

29283791

Publication Title

Robert C, Ribas A, Hamid O, Daud A, Wolchok JD, Joshua AM, Hwu WJ, Weber JS, Gangadhar TC, Joseph RW, Dronca R, Patnaik A, Zarour H, Kefford R, Hersey P, Zhang J, Anderson J, Diede SJ, Ebbinghaus S, Hodi FS. Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. J Clin Oncol. 2018 06 10; 36(17):1668-1674.